Eli Lilly’s Mounjaro peak sales could now top $68B – analyst; Elon Musk’s brain-chip company reels in $280M
A few months ago, BMO Capital analyst Evan Seigerman estimated Eli Lilly’s type 2 diabetes drug Mounjaro would have more than $50 billion in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
